The novel treatment products in the treatment of haemophilia and other bleeding disorders have been a ‘hot topic’ of discussion already for several years. Many questions have been raised and many answers have been provided.
However, it is only for a couple of years, or in some places even less, that one of these novel agents – bi-specific antibody – has been actually accessible to the patients with inhibitors. This has not been long enough time to build the sufficient volume of post marketing data, nor have all the questions answered. However, the experience among the patients and healthcare professionals is gradually accumulating and more and more answers can be provided.
The October edition of “Happy 1/2 Hour with an Expert in Haemophilia Care” – to take place on Wednesday, 28 October at 19:00 Brussels time – will focus on discussing the question of “Immune tolerance induction and emicizumab”. Is it really necessary? If yes, what are the necessary preparations, modalities and protocols?
This event will be a closed video conference. To join please register here.
